Ancora Advisors’s ImmunityBio IBRX Stock Holding History

Ancora Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$153K	Hold	20,000	–	–	﹤0.01%	782
2025 Q4	$39.6K	Buy	20,000 +10,000	+100%	+$22.7K	﹤0.01%	1236
2025 Q3	$24.6K	Hold	10,000	–	–	﹤0.01%	1190
2025 Q2	$26.4K	Buy	+10,000	New	+$26.9K	﹤0.01%	1163

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ancora Advisors's IBRX Position: Q1 2026 in Review

Ancora Advisors held its ImmunityBio (IBRX) position steady in Q1 2026 at 20,000 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #782.

Ancora Advisors first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Ancora Advisors held 20,000 shares of ImmunityBio worth $153K as of Q1 2026.
Ancora Advisors left its ImmunityBio share count unchanged in Q1 2026.
ImmunityBio made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #782 holding.
Ancora Advisors first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.